Reason: Merged with Viewpoint Molecular
Last recorded trade on: April 21, 2023
Source: https://isoray.com/2023/02/isoray-completes-merger-with-viewpoint-molecular-targeting-to-advance-new-treatment-paradigm-in-targeted-precision-oncology-medicine/
P/E ratio for Isoray (ISR)
P/E ratio on April 21, 2023 (TTM): -5.49
According to Isoray 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -5.48571. At the end of 2021 the company had a P/E ratio of -7.76.
P/E ratio history for Isoray from 2005 to 2022
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2021 | -7.76 | -13.82% |
| 2020 | -9.00 | -13.52% |
| 2019 | -10.4 | 246.89% |
| 2018 | -3.00 | -17.36% |
| 2017 | -3.63 | |
| 2015 | -11.7 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 | -16.1 | 193.49% | 🇺🇸 USA |
 | 61.0 | -1,211.98% | 🇺🇸 USA |
 | 30.6 | -657.91% | 🇺🇸 USA |
 | 21.7 | -495.09% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.